Parabilis Medicines raises $745m in upsized Nasdaq IPO

Parabilis Medicines has priced its initial public offering on the Nasdaq Global Select Market at $20.00 per share, raising gross proceeds of $670 million from 33.5 million shares. A concurrent private placement to Regeneron Pharmaceuticals adds a further $75 million, bringing the total anticipated raise to approximately $745 million before underwriting costs and fees. The company trades under the ticker PBLS, with shares expected to have begun trading on 10 June 2026 and the offering scheduled to close on or about 11 June.

The offering was upsized from its initial filing, a signal of strong institutional appetite. Underwriters were granted a 30-day option to acquire a further 5,025,000 shares at the IPO price, which, if exercised in full, would lift gross IPO proceeds to roughly $770 million. Leerink Partners, BofA Securities, Evercore ISI and Guggenheim Securities acted as active book-running managers, with LifeSci Capital serving as passive bookrunner.

The Regeneron angle

Perhaps the most strategically significant element of the transaction is Regeneron's direct participation. The large-cap biopharma agreed to purchase 4,166,666 shares at $18.00 per share, a 10 per cent discount to the IPO price, in a private placement that is contingent on the public offering closing but not vice versa. The involvement of an established platform company as a cornerstone investor at the pricing stage typically provides a signal of scientific credibility to the wider market, though it does not constitute a partnership or licensing agreement and should not be read as one.

Parabilis describes itself as built around a proprietary modality called Helicons, which the company characterises as stabilised helical peptides engineered to engage protein targets that have historically resisted small-molecule and antibody approaches. The company says its platform is positioned to address so-called undruggable targets, a concept that has attracted significant investment across the sector over the past decade. The release did not name the specific indications in active clinical development, nor did it disclose trial phase, patient cohorts or interim efficacy data.

Market context

The Parabilis IPO arrives during a cautiously recovering window for biotech public markets. After a prolonged drought in life sciences listings through 2023 and 2024, the Nasdaq biotech index has seen a modest re-opening for clinical-stage companies with differentiated platform stories and credible investor syndicates in 2025 and into 2026. Raises of this magnitude remain rare for pre-revenue biotechs and typically require either late-stage clinical assets or a compelling platform narrative backed by institutional names.

The helical peptide and constrained peptide space has attracted growing interest as a bridge between small molecules and biologics, with several academic spinouts and venture-backed companies pursuing related chemistry. Parabilis has not named direct competitors in its public materials, and the editorial team has not independently verified specific comparator programmes. Investors will be watching for a prospectus filing that names lead indications, clinical timelines and use-of-proceeds allocation, which will be the clearest indicator of how the $745 million will be deployed and on what timeline milestones can be expected.